

## Ozoralizumab: Adis Evaluation

### Key Points

- A trivalent anti-TNF $\alpha$  NANOBODY<sup>®</sup> compound developed by Taisho Pharmaceutical Co. Ltd (under license from Ablynx, an affiliate of Sanofi) for the treatment of RA
- Received its first approval on 26 September 2022 in Japan
- Approved for use in the treatment of RA that is inadequately managed by current available treatments

### Summary

Ozoralizumab (Nanzora<sup>®</sup>), a trivalent anti-tumour necrosis factor alpha (TNF $\alpha$ ) NANOBODY<sup>®</sup> compound, has been developed by Taisho Pharmaceutical Co. Ltd (under license from Ablynx, an affiliate of Sanofi) for the treatment of rheumatoid arthritis (RA).

In September 2022, ozoralizumab was approved in Japan for the treatment of RA that is inadequately managed by current available treatments.

This summary represents the opinions of the [author/authors]. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. © Springer Nature Switzerland AG 2022.